

# Javier Gallego

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2674314/publications.pdf>

Version: 2024-02-01

34  
papers

605  
citations

623188

14  
h-index

610482

24  
g-index

34  
all docs

34  
docs citations

34  
times ranked

997  
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of Thrombosis-Related Genes in Patients with Advanced Gastric Cancer: Data from AGAMENON-SEOM Registry. <i>Biomedicines</i> , 2022, 10, 148.	1.4	4
2	SEOM-GEMCAD-TTD Clinical Guideline for the diagnosis and treatment of esophageal cancer (2021). <i>Clinical and Translational Oncology</i> , 2022, 24, 658-669.	1.2	8
3	Cell-free circulating tumor DNA in colorectal cancer: a proof of concept with simplified methodology. <i>Clinical and Translational Oncology</i> , 2022, , .	1.2	0
4	External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit?. <i>Gastric Cancer</i> , 2021, 24, 445-456.	2.7	7
5	Controversies in the treatment of RAS wild-type metastatic colorectal cancer. <i>Clinical and Translational Oncology</i> , 2021, 23, 827-839.	1.2	3
6	External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110196.	1.4	5
7	Clinical Impact of Presurgery Circulating Tumor DNA after Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer: A Biomarker Study from the GEMCAD 1402 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 2890-2898.	3.2	44
8	Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial. <i>European Journal of Cancer</i> , 2021, 145, 158-167.	1.3	26
9	Causal considerations can inform the interpretation of surprising associations in medical registries. <i>Cancer Investigation</i> , 2021, , 1-27.	0.6	11
10	Optimal duration of first-line chemotherapy for advanced gastric cancer: data from the AGAMENON registry. <i>Clinical and Translational Oncology</i> , 2020, 22, 734-750.	1.2	8
11	Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long term results. <i>BMC Cancer</i> , 2020, 20, 1164.	1.1	7
12	Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry. <i>PLoS ONE</i> , 2020, 15, e0235848.	1.1	14
13	SEOM clinical guideline for the diagnosis and treatment of gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJA) (2019). <i>Clinical and Translational Oncology</i> , 2020, 22, 236-244.	1.2	28
14	Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry. , 2020, 15, e0235848.		0
15	Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry. , 2020, 15, e0235848.		0
16	Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry. , 2020, 15, e0235848.		0
17	Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry. , 2020, 15, e0235848.		0
18	Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab. <i>Drugs in R and D</i> , 2019, 19, 267-275.	1.1	4

#	ARTICLE	IF	CITATIONS
19	Multistate Models: Accurate and Dynamic Methods to Improve Predictions of Thrombotic Risk in Patients with Cancer. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1849-1859.	1.8	24
20	SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018). <i>Clinical and Translational Oncology</i> , 2019, 21, 46-54.	1.2	40
21	Surgery for metastases for esophageal-gastric cancer in the real world: Data from the AGAMENON national registry. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1191-1198.	0.5	42
22	Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world data from the AGAMEMON National Cancer Registry. <i>Gastric Cancer</i> , 2018, 21, 96-105.	2.7	16
23	Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 321-335.	1.2	27
24	Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients. <i>Neoplasia</i> , 2018, 20, 678-686.	2.3	7
25	Impact of primary tumour location (PTL) on outcomes in patients (pts) with metastatic colorectal cancer (mCRC) undergoing first-line panitumumab (Pmab) + FOLFIRI treatment .. <i>Journal of Clinical Oncology</i> , 2018, 36, 820-820.	0.8	1
26	Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab. <i>British Journal of Cancer</i> , 2017, 116, 1526-1535.	2.9	46
27	Biomarkers in pancreatic ductal adenocarcinoma. <i>Clinical and Translational Oncology</i> , 2017, 19, 1430-1437.	1.2	10
28	First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD). <i>European Journal of Cancer</i> , 2017, 81, 191-202.	1.3	68
29	Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry. <i>British Journal of Cancer</i> , 2017, 117, 775-782.	2.9	77
30	Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer. <i>Gastric Cancer</i> , 2017, 20, 465-474.	2.7	20
31	Identification of gene expression profiling associated with erlotinib-related skin toxicity in pancreatic adenocarcinoma patients. <i>Toxicology and Applied Pharmacology</i> , 2016, 311, 113-116.	1.3	15
32	A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features. <i>BMC Cancer</i> , 2015, 15, 60.	1.1	41
33	SEOM clinical guidelines for the treatment of oesophageal cancer. <i>Clinical and Translational Oncology</i> , 2011, 13, 520-524.	1.2	2
34	Towards an optimal treatment strategy for patients with oesophageal cancer. <i>Clinical and Translational Oncology</i> , 2008, 10, 131-133.	1.2	0